Media

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

February 27, 2026

RenovoRx today announced continued commercial progress, with 12 U.S. cancer centers now utilizing the RenovoCath device. These 12 centers are in addition to those centers currently using RenovoCath as part…

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

February 26, 2026

RenovoRx today announced that a clinical data abstract submission by cancer experts at Moffitt Cancer Center to the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting has been accepted.

RenovoRx Establishes RenovoCath® Medical Advisory Board

February 10, 2026

RenovoRx today announced the formation of a dedicated RenovoCath Medical Advisory Board (“MAB”) to support its clinical and strategic initiatives.

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

February 5, 2026

RenovoRx is pleased to announce the appointment of Mark Voll as the Company’s Chief Financial Officer, effective February 1, 2026.

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

February 4, 2026

RenovoRx today announced that new clinical data will be presented at the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting on February 6, 2026. The clinical data abstract entitled,…

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

January 28, 2026

RenovoRx today announced that its abstract submission to the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting has been accepted. The meeting will be held February 4–8, 2026 in Savannah, Georgia.

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

January 20, 2026

RenovoRx today announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company’s RenovoCath patented FDA-cleared drug-delivery device into oncology treatment programs.

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

January 8, 2026

RenovoRx today announced that a new clinical data abstract from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial will be presented at the American…

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

December 11, 2025

RenovoRx is pleased to announce that its abstract submission to the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 (“ASCO GI”) has been accepted.

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

November 6, 2025

RenovoRx today announced the appointment of renowned UCLA surgeon and pancreatic disease expert Timothy Donahue, MD, to RenovoRx’s scientific advisory board (SAB).

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

October 13, 2025

RenovoRx today announced the appointment of renowned interventional oncologist Thierry de Baère, MD, PhD to RenovoRx’s Scientific Advisory Board (SAB).

RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

September 25, 2025

RenovoRx today announced that the first registry-eligible patient procedure in its PanTheR Post-Marketing Registry Study (NCT06805461) has been successfully completed at the University of Vermont Cancer Center.

* Individual results may vary.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Media

Press Releases

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx Establishes RenovoCath® Medical Advisory Board

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

In the News

Mark Voll Joins RenovoRx as Chief Financial Officer

Why Commercial Discipline Starts Long Before Launch

Interview with Shaun Bagai: Revolutionary Cancer Treatment, Startup Success, & Medtech Mentorship

Nanoparticles and Beyond: Novel Drug Delivery Strategies for Cancer

Revolutionizing Cancer Treatment: The Future of Localized Drug Delivery to Tumors with CEO Shaun Bagai

First Patient Treated in RenovoCath Clinical Trial

Expanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots

From Trials to Hope: A New Approach to Treating Pancreatic Cancer

RenovoRx Panther Study Progresses with First Clinical Procedure

How Skipping The CRO Helped RenovoRx Get Closer To Patients

PharmaShots Webinar: Mastering a Patient-Centric Approach for Treatment in Biopharma

RenovoRx Updates Pivotal TIGeR-PaC Trial of Pancreatic Cancer Treatment

Delivering Therapy Where it Matters

Quicklinks

Delivering Therapy Where it Matters

Quicklinks